- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01210404
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
June 6, 2011 updated by: Pfizer
Open Label Single Sequence Study To Estimate The Effect Of Filibuvir (PF-00868554) On S-And R-Methadone In Subjects Receiving Chronic Methadone Treatment And To Evaluate The Pharmacokinetics Of Filibuvir
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection.
Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Pfizer Investigational Site
-
Overland Park, Kansas, United States, 66212
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start.
Exclusion Criteria:
- Evidence of chronic diseases including HIV, HBV or HCV.
- Evidence of acute or chronic liver disease.
- Treatment with prescription or nonprescription drugs other than methadone within 7 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.0
|
Filibuvir, 600mg bid administered along with methadone on days 2-11
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Methadone plasma pharmacokinetic parameters, AUC24, Cmax
Time Frame: day 1
|
day 1
|
Methadone plasma pharmacokinetic parameters, AUC24, Cmax
Time Frame: day 11
|
day 11
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Methadone plasma pharmacokinetic parameters Tmax and C24h
Time Frame: day 1
|
day 1
|
Methadone plasma pharmacokinetic parameters Tmax and C24h
Time Frame: day 11
|
day 11
|
Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.
Time Frame: day 2
|
day 2
|
Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.
Time Frame: day 11
|
day 11
|
Safety and tolerability, including adverse events, vital signs, 12 lead ECG and lab safety assessments.
Time Frame: days 0-12
|
days 0-12
|
Symptoms of methadone withdrawal as assessed by short Opiate Withdrawal Scale, Desires for Drug questionnaire and pupillary diameter measurement .
Time Frame: days 0-12
|
days 0-12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
September 27, 2010
First Submitted That Met QC Criteria
September 27, 2010
First Posted (Estimate)
September 28, 2010
Study Record Updates
Last Update Posted (Estimate)
June 7, 2011
Last Update Submitted That Met QC Criteria
June 6, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A8121023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hospices Civils de LyonCompleted
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
Clinical Trials on filibuvir
-
PfizerCompletedHepatitis | Hepatitis CUnited States, Canada, Spain, Hungary, Korea, Republic of, Belgium, Germany, France, Puerto Rico
-
PfizerCompleted